Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 7

1.

A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.

Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA.

Oncogene. 1995 Feb 2;10(3):509-13.

PMID:
7845675
2.

The familial medullary thyroid carcinoma-associated RET E768D mutation in a multiple endocrine neoplasia type 2A case.

Aiello A, Cioni K, Gobbo M, Collini P, Gullo M, Della Torre G, Passerini E, Ferrando B, Pilotti S, Pierotti MA, Pasini B.

Surgery. 2005 May;137(5):574-6. No abstract available.

PMID:
15855933
3.

Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.

Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M.

Oncogene. 1997 Jul 24;15(4):393-402.

4.

RET mutations in exons 13 and 14 of FMTC patients.

Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, et al.

Oncogene. 1995 Jun 15;10(12):2415-9.

PMID:
7784092
5.

Familial prevalence and age of RET germline mutations: implications for screening.

Machens A, Dralle H.

Clin Endocrinol (Oxf). 2008 Jul;69(1):81-7. Epub 2008 Jul 1.

PMID:
18062802
6.

Mutation of RET codon 768 is associated with the FMTC phenotype.

Boccia LM, Green JS, Joyce C, Eng C, Taylor SA, Mulligan LM.

Clin Genet. 1997 Feb;51(2):81-5.

PMID:
9111992
7.

Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.

Jindrichová S, Vcelák J, Vlcek P, Neradilová M, Nemec J, Bendlová B.

J Endocrinol. 2004 Nov;183(2):257-65.

PMID:
15531714

Supplemental Content

Support Center